Patents Assigned to Merrell Dow Pharmaceuticals Inc.
  • Publication number: 20020077482
    Abstract: The present invention is related to a novel intermediates and processes which are useful in the preparation of certain antihistaminic piperidine derivatives of the formula 1
    Type: Application
    Filed: March 28, 2001
    Publication date: June 20, 2002
    Applicant: Merrell Dow Pharmaceuticals Inc.
    Inventors: Richard C. Krauss, Robert M. Strom, Carey L. Scortichini, William J. Kruper, Richard A. Wolf, Weishi W. Wu, Albert A. Carr, David A. Hay, Duane E. Rudisill, Gianbattista Panzone
  • Publication number: 20010031895
    Abstract: The present invention is related to a novel intermediates and processes which are useful in the preparation of certain antihistaminic piperidine derivatives of the formula 1
    Type: Application
    Filed: April 4, 2001
    Publication date: October 18, 2001
    Applicant: Merrell Dow Pharmaceuticals Inc.
    Inventors: Richard C. Krauss, Robert M. Strom, Carey L. Scortichini, William J. Kruper, Richard A. Wolf, Weishi W. Wu, Albert A. Carr, David A. Hay, Duane E. Rudisill, Gianbattista Panzone
  • Patent number: 5529995
    Abstract: The present invention relates to novel aminoacetylmercapto derivatives useful as inhibitors of enkephalinase and ACE.
    Type: Grant
    Filed: March 1, 1995
    Date of Patent: June 25, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Gary A. Flynn, Robert J. Cregge, Thomas L. Fevig, Shyam Sunder, Patrick W. Shum
  • Patent number: 5529996
    Abstract: The present invention relates to novel 2-substituted indane-2-mercaptoacetylamide derivatives which are useful as inhibitors of enkephalinase and ACE.
    Type: Grant
    Filed: March 1, 1995
    Date of Patent: June 25, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Alan M. Warshawsky, Gary A. Flynn
  • Patent number: 5525633
    Abstract: The present invention relates to novel triaryl-ethylene derivatives that are useful as anti-neoplastic agents, antiatherosclerotic agents, and hypocholesterolemic agents.
    Type: Grant
    Filed: June 15, 1994
    Date of Patent: June 11, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Donald P. Matthews, Alan J. Bitonti, William A. Van Sickle, Donald A. Kaplan
  • Patent number: 5514688
    Abstract: This invention relates to carbocyclic adenosine compounds of the formula (1) ##STR1## wherein the hydroxy substituent on the cyclopentanyl ring is in the CIS configuration relative to the bicyclic substituent,Y.sub.3, Y.sub.7, Y.sub.8 and Y.sub.9 are each independently nitrogen or a CH group,Q is NH.sub.2, halogen or hydrogen, andZ is hydrogen, halogen, or NH.sub.2 ;or a pharmaceutically-acceptable salt thereof, and to their use as immunosuppressants.
    Type: Grant
    Filed: May 12, 1994
    Date of Patent: May 7, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: David R. Borcherding, Carl K. Edwards, III, Ronald E. Esser
  • Patent number: 5512177
    Abstract: The narrow poly- or mono-dispersed oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a recurring unit of from 3 to 50. These oligomers are water-soluble, preferably have a rigid backbone, have recurring units coupled by carbonyl linking moities which have anionic groups, display predominantly linear geometry such that regular spacing between anionic groups exists in an aqueous medium, and are pharmaceutically-acceptable. The narrow poly- or mono-dispersed oligomers are useful for the treatment and/or diagnosis of AIDS and/or ARC or HSV.
    Type: Grant
    Filed: November 22, 1993
    Date of Patent: April 30, 1996
    Assignees: The Dow Chemical Co., Merrell Dow Pharmaceuticals Inc.
    Inventors: Alan D. Cardin, Michael J. Mullins, William A. Fordyce, Thomas A. Chamberlin, Michael J. Fazio
  • Patent number: 5504078
    Abstract: This invention relates to novel polyglycosidyl derivatives of 1-deoxy-nojirimycin, to the processes for their preparation and to their end-use applications, particularly as to their use in the treatment of diabetes.
    Type: Grant
    Filed: December 7, 1992
    Date of Patent: April 2, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Jean-Bernard Ducep, Charles Danzin
  • Patent number: 5500419
    Abstract: The present invention is directed to a new neuroprotective agent. The agent is R-4-oxo-5-phosphononorvaline. This agent is useful in the treatment of ischemic and hypoxic conditions such as stroke.
    Type: Grant
    Filed: December 20, 1994
    Date of Patent: March 19, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Jeffrey P. Whitten, Bruce M. Baron
  • Patent number: 5498778
    Abstract: The present invention is directed to a new class of cyclic nitrones and their use as spin trapping agents.
    Type: Grant
    Filed: December 9, 1994
    Date of Patent: March 12, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Albert A. Carr, Craig E. Thomas, Ronald C. Bernotas, George Ku
  • Patent number: 5494932
    Abstract: Sulfonic acid stilbenes block the infection of cells by HSV, and CMV and these compounds can be used to treat viral infection.
    Type: Grant
    Filed: May 25, 1994
    Date of Patent: February 27, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Alan D. Cardin, A. Stanley Tyms
  • Patent number: 5491136
    Abstract: The present invention is directed to a method of using a certain compounds which are 2,19-methyleneoxy or 2,19 methylenethio bridged steroids, and related steroidal compounds as inhibitors of the enzyme steroid aromarase, 19-hydroxylase and as treatment for various estrogen dependent/mediated disorders including hormonal dependent breast cancer.
    Type: Grant
    Filed: March 18, 1994
    Date of Patent: February 13, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Norton P. Peet, J. O'Neal Johnston, Joseph P. Burkhart
  • Patent number: 5491143
    Abstract: The present invention relates to certain novel mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and of ACE.
    Type: Grant
    Filed: April 5, 1995
    Date of Patent: February 13, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Gary A. Flynn, Philippe Bey, Alan M. Warshawsky, Douglas W. Beight, Shujaath Mehdi, Eugene L. Giroux, Timothy P. Burkholder, Edward D. Daugs, John F. French
  • Patent number: 5491142
    Abstract: The present invention relates to novel 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives which are useful as inhibitors of Enkephalise.
    Type: Grant
    Filed: March 1, 1995
    Date of Patent: February 13, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Alan M. Warshawsky, Gary A. Flynn
  • Patent number: 5491141
    Abstract: The present invention relates to novel 2-substitited indane-2-mercaptoacetylamide tricyclic derivatives which are useful as inhibitors of Enkephalise.
    Type: Grant
    Filed: March 1, 1995
    Date of Patent: February 13, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Alan M. Warshawsky, Gary A. Flynn
  • Patent number: 5491153
    Abstract: The present invention is directed to a new class of 3-amido and 3-sulfamido-indolyl NMDA antagonists and their use in the treatment of a number of disease states.
    Type: Grant
    Filed: January 13, 1995
    Date of Patent: February 13, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Francesco G. Salituro, Bruce M. Baron
  • Patent number: 5489579
    Abstract: The present invention is directed to a method for poteniating the therapeutic effects of selected NMDA antagonists.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: February 6, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Ian A. McDonald, Bruce M. Baron
  • Patent number: 5488047
    Abstract: The present invention relates to compounds of the formula ##STR1## wherein B.sub.1 and B.sub.2 are each independently hydrogen; hydroxy; --OR.sub.2 wherein R.sub.2 is a C.sub.1 -C.sub.4 alkyl or an Ar-Y group wherein Ar is aryl and Y is a hydrogen or C.sub.1 -C.sub.4 alkyl; or, where B.sub.1 and B.sub.2 are attached to adjacent carbon atoms, B.sub.1 and B.sub.2 can be taken together with said adjacent carbons to form a benzene ring or methylenedioxy;A is a bond, methylene or oxygen, sulfur or NR.sub.4 or NCOR.sub.5 wherein R.sub.4 is hydrogen, a C.sub.1 -C.sub.4 alkyl or an Ar--Y-- group and R.sub.5 is --CF.sub.3, a C.sub.1 -C.sub.10 alkyl or an Ar--Y-- group;R.sub.3 is hydrogen or --CH.sub.2 OC(O)C(CH.sub.3).sub.3 ;R.sub.1 is hydrogen, C.sub.1 -C.sub.4 alkyl or --CH.sub.2 OC(O)--C(CH.sub.3).sub.3 ; andn is an integer 1 to 3,which are useful as inhibitors of enkephalinase and ACE.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: January 30, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Alan M. Warshawsky, Gary A. Flynn
  • Patent number: 5488048
    Abstract: The present invention relates to novel aminoacetylmercapto derivatives useful as inhibitors of enkephalinase and ACE.
    Type: Grant
    Filed: March 1, 1995
    Date of Patent: January 30, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Gary A. Flynn, Robert J. Cregge, Thomas L. Fevig, Shyam Sunder, Patrick W. Shum
  • Patent number: 5488188
    Abstract: The present invention relates to a novel process for preparing (E)-1-amino-2-(fluoromethylene)-4-(p-fluorophenyl)butane, also known in the art as (E)-(p-fluorophenethyl)-3-fluoroallylamine, novel intermediates thereof, a novel process for the preparing (E)-2-(fluoromethylene)-4-(p-fluorophenyl)butan-1-ol, and a novel process for preparing alkali metal salts of diformylamide.
    Type: Grant
    Filed: September 29, 1994
    Date of Patent: January 30, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Jonathan C. Evans, Christian T. Goralski, Cynthia L. Rand, Paul C. Vosejpka